Ignyta is an oncology biotechnology company. The company focuses on integrated therapeutic (Rx) and companion diagnostic (Dx) strategies for treating cancer patients. Its Rx is focused on developing molecularly targeted therapies for eradicating residual disease. Its Dx focuses on pairing the product candidates with biomarker-based companion diagnostics that are designed to identify the patients who will benefit from the therapies it develops. The company was founded in 2011 and is headquartered in San Diego, California.